Predict your next investment

Corporation
HEALTHCARE | Biotechnology
evolutec.co.uk

See what CB Insights has to offer

Founded Year

1998

Stage

IPO | IPO

Total Raised

$11.06M

Date of IPO

8/2/2004

About Evolutec

Developer of human and veterinary medicines specializing in identifying and developing biologically active molecules derived from the saliva of blood-feeding arthropod parasites, particularly ticks. The company has developed a platform technology which enables it to isolate biologicallyactive compounds and identify the genes which code for these molecules. The company has identified in excess of 100 biologically active molecules with therapeutic potential and six have progressed into development. The most advanced projects address asthma and allergic conjunctivitis. The company's lead product is in clinical Phase II in USA for conjunctivitis and rhinitis.

Evolutec Headquarter Location

The Magdalen Centre

Oxford, OX4 4GA,

United Kingdom

44 186 578 4070

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.